AbbVie saves its skin by buying Allergan
Our expert's opinionAbbVie will no longer have a monopoly on Humiria, a treatment that brought them 60% of their turnover. To face this, AbbVie has turned to Botox produced by Allergan because this product doesn’t use any Brevet. The merger of these two companies is expected to generate $19 billion, which would repay the debt and also exploit existing materials to create new products.
Impressive rebound. The American company was able to anticipate the flaws and rebounded with a “bold” solution. What do you think about it?
- Nora Jamai, Associate Consultant
Other insights in Pharmaceutical Affairs
Read our insight
Working as a pharma professional at Strand: what is it like?